First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.

被引：0
|
作者：
Niho, S [1 ]
Kubota, K [1 ]
Goto, K [1 ]
Yoh, K [1 ]
Ohmatsu, H [1 ]
Kakinuma, R [1 ]
Nishiwaki, Y [1 ]
机构：
[1] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7059
引用
收藏
页码：631S / 631S
页数：1
相关论文
共 50 条
  • [1] A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).
    Suzuki, R
    Hasegawa, Y
    Baba, K
    Saka, H
    Saito, H
    Taniguchi, H
    Yamamoto, M
    Matsumoto, S
    Kato, K
    Shimokata, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
  • [2] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Saijo, N
    Nishiwaki, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 64 - 69
  • [3] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin1
    [J]. The Journal of Biomedical Research, 2009, (06) : 392 - 397
  • [4] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
    Yin Y.-M.
    Geng Y.-T.
    Shao Y.-F.
    Hu X.-L.
    Li W.
    Shu Y.-Q.
    Wang Z.-X.
    [J]. Journal of Experimental & Clinical Cancer Research, 29 (1)
  • [5] First-Line Single Agent Treatment With Gefitinib in Advanced Non-Small-Cell Lung Cancer Patients
    Yin, Yong-mei
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 325 - 325
  • [6] Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC).
    Williams, CC
    Haura, EB
    Antonia, SJ
    Chiappori, A
    Bepler, G
    Simon, GR
    Moffitt, HL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [7] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [8] A new docetaxel (D) gemcitabine (G) regimen as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase II study.
    Morere, JF
    Terrioux, P
    Brechot, JM
    Tredaniel, J
    Bouchahda, M
    Duhamel, JP
    Mandet, J
    Brain, E
    Beerblock, K
    Fellague, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 692S - 692S
  • [9] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
    Suzuki, R.
    Hasegawa, Y.
    Baba, K.
    Saka, H.
    Saito, H.
    Taniguchi, H.
    Yamamoto, M.
    Matsumoto, S.
    Kato, K.
    Oishi, T.
    Imaizumi, K.
    Shimokata, K.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1599 - 1603
12345